Committees

Charter

The Business Development & Finance Committee (BDF) strives to:

• address the evolving CGT business model and key considerations including clinical development, partnerships, financing, and commercialization.
  
  

Projects & Objectives

• The BDF champions the ISCT Investigators to Investors (I to I) program, which strives to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. 
• Conducts semi-annual surveys with aim to understand investor perceptions of key opportunities and challenges in the CGT field at the time.
• Curates topical educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing for both the investor and investigator profiles 
  
  

Ideal Member Profile

• Business development executives (e.g., CEOs, SVPs/VPs, etc.)
• Cell and Gene Therapy investors & analysts, by invitation
  
  

Recent Publications

Cell and gene therapy: a snapshot of investor perspectives (Cytotherapy. 2021 May; 23(3):256-260)
A roadmap for cost-of-goods planning to guide economic production of cell therapy products (Cytotherapy. 2017 Dec;19(12):1383-1391)

The Committee

Co-Chair

Sven Kili, MBChB, MRCS (Eng)

Sven Kili Consulting
Saisei Ventures
CCRM 
United Kingdom

Co-Chair

Patrick Rivers, MBA

Aquilo Capital
United States

2024 Members

Sophie Bardy
BioBridge Global

Ksenia Bezverbnaya
CCRM

Ann Brady
Avectas

Daniela Buchmayr
Sarcura GMBh

Dan Catron
CTMC

Matthieu Coutet
Sofinnova Partners

Romain de Rauville
ExoXpert

Mark Flower
Cryoport Systems

Jules Foster
Lonza

Ingrid Gafanhão
Bryan, Garnier & Co

Asthika Goodwardene
Truist

Brian Hawkins
PluristyX

Traci Kyes
Virocell Biologics

Jake Lesnik
Mekenos

Jeff Liter
Luminary TX

Jennifer Manning
BioCentriq

Adam McPherson
OriGen Biomedical

Marie-Laure Muiras
BioMérieux

Lise Munsie
CCRM

Joseph Oved
Memorial Sloan Kettering Cancer Center

Eck Redmond
NMDP

Antonio Scatena
Gateway Analytical

Nathan Smith
Cell Therapies Pty Ltd

John So
Fujifilm Irvine Scientific

Mathias Svahn
Next Cell Pharma

Steven Thompson
BioLife Solutions

Franziska Uber
PL BioScience GmhH

Geoff Uhl
Terumo BCT

Philip Vanek
Gamma Biosciences

Jonathan Yeh
Saisei Ventures

Victoria Zellmer
MaxCyte

Julia Zhen
Thermo Fisher Scientific

Sanjin Zvonic
Dark Horse Consulting